Mean cost of bringing new drug to US market is $879.3 million, study estimates

Published Date: 03 Jul 2024

The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are considered, according to a study published online June 28 in JAMA Network ...

Read Full News

Latest News

Gene-Agnostic Therapy Sees 3-Year Gain in Severe Vision Loss

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved functional vision in advanced severe vision loss.

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved functional vision in advanced severe vision loss.

Navigating Sustained Delivery in nAMD: An Interactive Clinical Decision-Making Simulation

Navigating Sustained Delivery in DME: An Interactive Clinical Decision-Making Simulation

Beyond Intravitreal Injections: Advancing Retinal Vascular Disease Care With Sustained Delivery Therapies

Focus Aligned: Patient Selection and Counseling for Pharmacologic Presbyopia Therapies

Focus Reengineered: Mechanisms and Clinical Data for Pharmacologic Presbyopia Therapies

News All Time

One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk

But it's not time to prescribe tirzepatide outside current indications, expert says

Color Blindness and Bladder Cancer: A Bad Combination for Survival?

Study suggests inability to identify blood in urine may delay diagnosis and reduce survival

Cardiovascular Risk Score Shows Value in Predicting Future Eye Disease

The score is commonly calculated in primary care

People, Faces Appeared Smaller Than Usual in Patient's Rare Case

63-year-old had an atypical cause of Alice in Wonderland Syndrome

Contaminated Water Blamed for 10 Deaths; FDA Rejections; Mammograms for Heart Risks?

Health news and commentary gathered by MedPage Today staff

FDA OKs More Eye Drops That Can Replace Reading Glasses

Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss

Sleeping With Two Pillows May Raise Internal Eye Pressure in Glaucoma

Stacked pillows alter the neck position and may compress the jugular, researchers suggest

Teen Boy Grows a Tooth Between Eyelid and Eyebrow

The 16-year-old underwent surgery to remove an ectopic canine tooth in left eye's superior orbit

Study Adds Fuel to the Debate Over Cataract Surgery and Wet AMD

Earlier concerns about surgery accelerating AMD progression likely overstated, researcher says

Hospital Had Ties to Epstein; Naked Knifeman at Eye Doctor; Health Department Probed

Health news and commentary gathered by MedPage Today staff

Some Blind Fans to Experience Super Bowl With Tactile Device That Tracks Ball

About 10 blind and low-vision fans will have an opportunity to use the technology

CDC Study Warns of Vision-Threatening Eye Infections After Laser Surgery

Three patients at New York City clinic developed fungal keratitis caused by a mold

Dry Eye: Handmaiden to Many Autoimmune Conditions, Not Just Sjogren's Disease

Taiwanese study puts numbers to common but poorly studied phenomenon

Retinopathy Risk With Long-Term HCQ Treatment Detailed in Meta-Analysis

Eye damage remains uncommon after 15 years, but certain factors increase the risk

Glaucoma Checks in Primary Care; Wastewater to Screen for Colorectal Cancer

Also in TTHealthWatch: new cholesterol management guidelines

Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs

First evidence of formulation-specific difference, significantly higher in men than women

Recommended News For You

CDC Alerts on Dramatic Rise in Human Parvovirus B19

What Patients Hear From Us: 'Blah, Blah, Tumor, Blah, Blah, Cancer'

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.

Recommended Articles For You

Understanding Macrocytosis: Causes, Symptoms, and Treatment Options  

Unlocking the Mysteries of ICD 10 Code Normocytic Anemia 

Unlocking the Mystery of Ovarian Cancer Staging 

Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

1.

The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy

2.

The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond

3.

Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense

4.

New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results

5.

Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

2.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot